Artemis Medicare Services Limited

rs,

Kurla Complex, Bandra (E), Mumbai – 400 051 The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 NSE Code: ARTEMISMED Scrip Code: 542919 Sub: Revised Earnings

68%

9M FY2024 Artemis Hospitals : At a Glance Established in July 2007 by promoters of Apollo Tyres (68% ownership), Artemis Hospital is one of the leading healthcare service providers in Delhi NCR • 71

Rs. 2,188

8 Daffodils by Artemis Cardiac Centres 2 Financial Highlights – Q3 FY24 Q3 FY24 Net Revenue Rs. 2,188 mn +16.7% YoY EBITDA Rs. 344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margi

16.7%

by Artemis Cardiac Centres 2 Financial Highlights – Q3 FY24 Q3 FY24 Net Revenue Rs. 2,188 mn +16.7% YoY EBITDA Rs. 344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY2

Rs. 344

c Centres 2 Financial Highlights – Q3 FY24 Q3 FY24 Net Revenue Rs. 2,188 mn +16.7% YoY EBITDA Rs. 344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY24 Net Revenue Rs. 6

28.3%

Financial Highlights – Q3 FY24 Q3 FY24 Net Revenue Rs. 2,188 mn +16.7% YoY EBITDA Rs. 344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY24 Net Revenue Rs. 6,533 mn +

15.7%

al Highlights – Q3 FY24 Q3 FY24 Net Revenue Rs. 2,188 mn +16.7% YoY EBITDA Rs. 344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY24 Net Revenue Rs. 6,533 mn +20.5% YoY

Rs. 116

3 FY24 Net Revenue Rs. 2,188 mn +16.7% YoY EBITDA Rs. 344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY24 Net Revenue Rs. 6,533 mn +20.5% YoY EBITDA Rs. 1,002 mn +36.8%

12.5%

Revenue Rs. 2,188 mn +16.7% YoY EBITDA Rs. 344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY24 Net Revenue Rs. 6,533 mn +20.5% YoY EBITDA Rs. 1,002 mn +36.8% YoY 15.3

5.3%

Rs. 2,188 mn +16.7% YoY EBITDA Rs. 344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY24 Net Revenue Rs. 6,533 mn +20.5% YoY EBITDA Rs. 1,002 mn +36.8% YoY 15.3% Margin

Rs. 6,533

344 mn +28.3%YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY24 Net Revenue Rs. 6,533 mn +20.5% YoY EBITDA Rs. 1,002 mn +36.8% YoY 15.3% Margin Net Profits Rs. 348 mn +27.6% YoY 5.3% M

20.5%

YoY 15.7% Margin Net Profits Rs. 116 mn 12.5% YoY 5.3% Margin 9M FY24 Net Revenue Rs. 6,533 mn +20.5% YoY EBITDA Rs. 1,002 mn +36.8% YoY 15.3% Margin Net Profits Rs. 348 mn +27.6% YoY 5.3% Margin No

“The construction of our third tower remains on track and is poised to contribute significantly to our efficiencies post commencement of its operations in early FY25.”

“This will be further boosted by the hospitals under Daffodils and Artemis Lite brands reaching maturity.”

Note

4

Note

1. EBITDA Includes Other Income 2.Margins calculated on Net Revenue from Operations Dr. Devlina Chakravarty, Managing Director “We are pleased to announce the financial performance of Q3 FY24; one of the best-ever quarterly results despite it being a seasonally weak festive quarter. The optimization of our second tower has enabled us to maintain focus on enhancing financial and operational metrics. The construction of our third tower remains on track and is poised to contribute significantly to our efficiencies post commencement of its operations in early FY25. This will be further boosted by the hospitals under Daffodils and Artemis Lite brands reaching maturity. During the quarter, we focused on refining the payer mix and improving financial parameters, resulting in one of the highest-ever ARPOB in the industry. Our operational metrics including revenue share from international patients, ALOS and patient footfall affirm our role and recognition as a prominent centre for Medical Value

Note

1. EBITDA Includes Other Income 2.Margins calculated on Net Revenue from Operations 19 Q3 and 9M FY24 Financial Performance (Consolidated) (Rs. Million) Gross Revenue Net Revenue from Operations Other Income Total Income Operative Expenses Employee Benefit Expenses Other expenses EBITDA EBITDA Margin Depreciation and amortisation expenses EBIT EBIT Margin Finance Cost PBT Total tax PAT PAT Margin

Note

1. EBITDA Includes Other Income 2.Margins calculated on Net Revenue from Operations Q3 FY24 Q3 FY23 2,287 2,188 18 2,206 1,341 347 173 344 1,979 1,875 12 1,887 1,154 309 155 268 15.7% 14.3% 102 243 11.1% 80 163 48 116 84 185 9.9% 52 133 30 103 5.3% 5.5% YoY% 15.5% 16.7% 43.9% 16.9% 16.2% 12.2% 11.8% 28.3% 21.4% 31.4% 53.4% 22.8% 57.9% 12.5% Q2 FY24 2,376 2,250 24 2,274 1,414 341 152 366 16.3% 100 267 11.9% 79 188 53 135 6.0% QoQ% (3.7)% (2.8)% (26.3)% (3.0)% (5.2)% 1.6% 13.9% (6.0)% 2.1% (9.0)% 0.9% (13.2)% (9.5)% (14.7)% 9M FY24 9M FY23 6,865 6,533 55 6,588 4,062 1,029 495 1,002 15.3% 293 709 10.9% 227 482 134 348 5,702 5,421 50 5,471 3,397 894 448 732 13.5% 223 510 9.4% 144 366 93 273 YoY% 20.4% 20.5% 10.1% 20.4% 19.6% 15.2% 10.6% 36.8% 31.5% 39.1% 57.6% 31.8% 44.4% 27.6% 5.3% 5.0% 20 Q3 and 9M FY24 Financial Performance (Standalone) (Rs. Million) Gross Revenue Net Revenue from Operations Other Income Total Income Operative Expenses Employee Benefit Expenses Other expenses EBITDA EBI

Note

1. EBITDA Includes Other Income 2.Margins calculated on Net Revenue from Operations Q3 FY24 Q3 FY23 2,197 2,103 17 2,120 1,299 334 153 334 1,919 1,814 12 1,826 1,116 298 143 269 15.9% 14.8% 96 80 238 11.3% 76 163 48 115 189 10.4% 49 140 32 108 5.5% 5.9% YoY% 14.5% 15.9% 42.4% 16.1% 16.4% 11.8% 7.4% 24.3% 20.4% 26.0% 54.0% 16.1% 47.9% 6.7% Q2 FY24 2,290 2,169 25 2,194 1,364 328 144 358 16.5% 94 264 12.2% 75 189 52 138 6.3% QoQ% (4.1)% (3.1)% (31.0)% (3.4)% (4.8)% 1.6% 6.7% (6.6)% 2.2% (9.8)% 1.2% (14.1)% (8.1)% (16.4)% 9M FY24 9M FY23 6,603 6,284 54 6,338 3,917 988 456 977 5,553 5,273 49 5,322 3,298 866 416 742 15.5% 14.1% 276 701 212 529 11.2% 10.0% 215 486 134 352 136 393 100 293 5.6% 5.6% YoY% 18.9% 19.2% 10.6% 19.1% 18.8% 14.1% 9.4% 31.7% 30.0% 32.4% 57.6% 23.7% 33.7% 20.3% 21 Disclosure This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other state